Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Myeloid Cell Marker Antibody (BM-1), DyLight 755, Novus Biologicals™

Mouse Monoclonal Antibody
Supplier: Novus Biologicals NBP234562IR
Description
Myeloid Cell Marker Monoclonal specifically detects Myeloid Cell Marker in Human samples. It is validated for Flow Cytometry, Immunohistochemistry, Immunocytochemistry/Immunofluorescence, Immunohistochemistry-Paraffin.Specifications
Myeloid Cell Marker | |
Monoclonal | |
DyLight 755 | |
Mouse | |
183 kDa | |
0.1 mL | |
Primary | |
Human | |
Purified |
Flow Cytometry, Immunocytochemistry, Immunofluorescence, Immunohistochemistry (Paraffin), Immunohistochemistry (Frozen) | |
BM-1 | |
Flow Cytometry, Immunocytochemistry/Immunofluorescence, Immunohistochemistry-Paraffin, Immunohistochemistry-Frozen | |
Human peripheral blood mononuclear cells | |
Protein A or G purified | |
RUO | |
Recognizes 183kDa protein with DNA-binding characteristics, which is identified as a myeloid specific antigen. It reacts with myeloid precursor cells and granulocytes in bone marrow. Its antigen appears to be restricted to M2 and M3 acute myelogenous leukemia (AML) subtypes. Markers of myeloid cells are useful in the identification of different levels of cellular differentiation. This monoclonal antibody reacts with early precursor and mature forms of human myeloid cells. It is useful in the identification of myelogenous leukemias, distinguishing granulocytic sarcomas from lymphoid malignancies and also in the study of differentiation and transformation of human myeloid cells. The biological function of this antigen is not clear, although it has been proposed that it may play a role in the differentiation of myeloid cells. | |
Store at 4C in the dark. | |
IgG1 κ |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
For Research Use Only
Spot an opportunity for improvement?Share a Content Correction